News

Regenacyn is formulated from the company’s Microcyn Technology platform and is designed to address the underserved consumer scar management market. The company said that the hydrogel has been

The trial is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of G1T28-1 in healthy volunteers, who are currently being enrolled in the Netherlands. The company is conducting

OPT-UP is a U.S.-based, multicenter longitudinal clinical research study that will enroll 2500 people with MS and follow them for up to five years. The goals of the

A second report, a PhRMA-sponsored white paper by Boston Healthcare Associates, Inc. (BHA), "The Value of Innovation in HIV/AIDS Therapy," highlights the progress in HIV/AIDS treatment and its

Outsourcing facilities were created under the federal Drug Quality and Security Act (DQSA) enacted in November 2013. Under the agreement, Cantrell Drug Company will prepare sterile compounded medications

Cipralex had annual sales of approximately $260 million in Canada , based on IMS Brogan sales data as of July 10, 2014. PrTeva-Escitalopram is available immediately in pharmacies

As part of the deal, Genmab will pay an upfront fee of $11m for exclusive rights to use Seattle’s auristatin-based ADC technology with its HuMax-AXL, an antibody targeting

VC-01 has recently secured clearance from the US Food and Drug Administration (FDA) to initiate evaluation in human clinical trials. The company’s stem cell-based therapy has been supported

Arixtra is indicated to treat prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip fracture surgery, including extended prophylaxis, hip